Scope of Lymphadenectomy Not Tied to Esophageal CA Survival

This article originally appeared here.
Share this content:
Scope of Lymphadenectomy Not Tied to Esophageal CA Survival
Scope of Lymphadenectomy Not Tied to Esophageal CA Survival

FRIDAY, Sept. 4, 2015 (HealthDay News) -- For patients undergoing esophageal cancer surgery, the extent of lymphadenectomy seems not to influence all-cause or disease-specific survival, according to a study published online Sept. 2 in JAMA Surgery.

Jesper Lagergren, M.D., Ph.D., from the Guy's and St. Thomas' NHS Foundation Trust in London, and colleagues examined data from a cohort of patients who underwent esophagectomy for cancer in 2000 to 2012 at a high-volume hospital, with follow-up until 2014.

The researchers found that 83.5 percent of the 606 included patients had adenocarcinoma of the esophagus. Fifty-three percent of participants died within five years of surgery and 39 percent died of tumor recurrence. There was no significant association between the extent of lymphadenectomy and all-cause or disease-specific mortality, irrespective of the categorization of lymphadenectomy or stratification for T category, calendar period, or chemotherapy. There was no significant reduction in all-cause five-year mortality for patients in the fourth versus the lowest quartile of the number of removed nodes (21 to 52 versus 0 to 10 nodes; hazard ratio, 0.86; 95 percent confidence interval, 0.63 to 1.17), particularly not in the most recent calendar period (hazard ratio, 0.98; 95 percent confidence interval, 0.57 to 1.66) for years 2007 to 2012.

"This study indicated that the extent of lymphadenectomy during surgery for esophageal cancer might not influence five-year all-cause or disease-specific survival," the authors write. "These results challenge current clinical guidelines."

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »